Your browser doesn't support javascript.
loading
Structural study of ponatinib in inhibiting SRC kinase.
Guo, Ming; Duan, Yankun; Dai, Shuyan; Li, Jun; Chen, Xiaojuan; Qu, Lingzhi; Chen, Zhuchu; Wei, Hudie; Jiang, Longying; Chen, Yongheng.
Afiliación
  • Guo M; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Duan Y; Department of Infectious Diseases & State Local Joint Engineering Laboratory for Anticancer Drugs, XiangYa Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Dai S; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Li J; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Chen X; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Qu L; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Chen Z; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Wei H; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Jiang L; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; Department of Pathology, XiangYa Hosp
  • Chen Y; Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. Electronic address: yonghenc@163.com.
Biochem Biophys Res Commun ; 598: 15-19, 2022 04 02.
Article en En | MEDLINE | ID: mdl-35151199
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridazinas / Familia-src Quinasas / Inhibidores de Proteínas Quinasas / Imidazoles Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridazinas / Familia-src Quinasas / Inhibidores de Proteínas Quinasas / Imidazoles Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China